Loading clinical trials...
Loading clinical trials...
An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic Pain
Conditions
Interventions
Qutenza (capsaicin) 8% topical system
capsaicin 0.04% topical system
Locations
64
United States
Tucson Orthopaedic Institute
Tucson, Arizona, United States
ILD Research Center
Vista, California, United States
International Spine, Pain, and Performance Center
Washington D.C., District of Columbia, United States
South Lake Pain Institute
Clermont, Florida, United States
University Clinical Research - DeLand Clinical Research Unit
DeLand, Florida, United States
Florida Research Center, Inc.
Miami, Florida, United States
Start Date
July 13, 2021
Primary Completion Date
March 7, 2025
Completion Date
August 28, 2025
Last Updated
October 15, 2025
Lead Sponsor
Averitas Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions